International Stem Cell Corp (OTC:ISCO) is an early-stage cell therapy company currently in clinical trials to treat Parkinson’s disease (PD). In November, the company presented interim six-month results from the first cohort of four patients in its Phase I trial of ISC-hpNSC in PD. Positive signals were seen in a variety of measures, which include daily living, mobility, depression and compulsive disorders.
Second cohort enrolled in PD trial
In March 2018, the company announced it had completed dosing of the second cohort of four patients in its Phase I trial of ISC-hpNSC in PD, who are being treated with the 50m cell dose. As a reminder, patients on the study are being treated in three cohorts with 30m, 50m and 70m stem cells, delivered via intracranial injection. Interim data from the first cohort, who were treated at the 30m cell dose, are encouraging. The company expects to start a Phase II PD trial later in 2018.
To read the entire report Please click on the pdf File Below: